Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept

Sherif, Amir; Hasan, Mudhar N.; Marits, Per; Karlsson, Matilda; Winqvist, Ola; Thörn, Magnus

doi:10.1016/j.eururo.2009.09.026

Cited by 28 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors have previously developed and described an adoptive immunotherapy method based on T cells collected from SNs or MNs [14,15]. The method expands effector memory T lymphocytes which, when reinfused, may result in a sustained response against tumor cells and, possibly, induce a state of vaccination [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer

Sherif

Hasan

Radecka

et al. 2015

Scandinavian Journal of Urology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer

Sherif

Hasan

Radecka

et al. 2015

Scandinavian Journal of Urology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Progress in the field of tumor immunology has made immunotherapy an attractive approach in trying to treat cancer. However, these efforts have mainly focused on tumor-reactive T cells (1)(2)(3)(4). Less attention has been paid to B cells and their role in host defense against tumors (5).…”

mentioning

confidence: 99%

Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies

Zirakzadeh

Marits

Sherif

et al. 2013

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

B lymphocytes contribute to immune surveillance, by tumor-specific Abs and Ag presentation to T lymphocytes, but are insufficiently studied in humans. In this article, we report a flow cytometric investigation of B lymphocyte subpopulations in blood, lymph nodes (LNs), and malignant tissues from 20 patients operated on because of advanced solid tumors. The CD19+ compartment in peripheral blood was essentially unaltered in patients, as compared with healthy control subjects. In metastatic LNs, signs of B lymphocyte activation were observed, as evidenced by increased proportions of plasmablasts and CD86-expressing cells. In tumor-infiltrating B lymphocytes (TIL-B), both switched memory cells and plasmablasts were expanded, as compared with nonmalignant epithelium. Moreover, pronounced skewing of Igλ/Igκ ratio was evident among TIL-Bs. By spectratype analysis on IgH, we confirmed a monoclonal expansion of the Vh7 family in TIL-B, also present in a tumor-associated LN. Sequencing the clonally expanded Vh7 revealed signs of somatic hypermutation. In conclusion, B lymphocytes in cancer patients exhibit signs of activation in tumor-associated tissues, likely induced by recognition of tumor Ags. Increased numbers of switched memory cells and plasmablasts in combination with clonal expansion and signs of somatic hypermutation suggest a CD4+ T lymphocyte–dependent antitumoral response, which may be exploited for immunotherapy.

show abstract

“…ACT yielded excellent clinical results in patients with metastatic melanoma and has also provided promising data in a variety of neoplasms [30]. The expansion of autologous sentinel node-derived T cells showed objective responses in bladder cancer in phase I trials [31,32] and the preclinical development of tumor-infiltrating lymphocytes showed encouraging activity in RCC [33]; a few trials also support the use of chimeric antigen receptors or genetically engineered T cells against prostate cancer [34,35]. Nevertheless, the high costs, potential delayed side effects [36], and the need for adequate cell manufacturing facilities have limited the pace of development of ACT in clinical practice to date.…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy for genitourinary cancer

et al. 2016

View full text Add to dashboard Cite

In the last few years, cancer immunotherapy has changed the natural history and treatment strategies of a number of solid tumors, including melanoma and lung cancer. The anti-PD-1 nivolumab showed a survival benefit compared with everolimus in the second-line treatment of renal cell carcinoma, resulting in a radical shift in perspective in the treatment of this neoplasia and suggesting a new scenario beyond tyrosine kinase inhibitors. Checkpoint inhibitors might also improve the treatment of urothelial cancer, considering the promising results achieved so far and the relatively low efficacy of currently available treatments. Sipuleucel-T was the first approved immunotherapy for prostate cancer, showing a clear benefit in overall survival, and paved the way for the clinical testing of other novel cancer vaccines. This review provides a comprehensive overview of the current knowledge and new perspectives of immunotherapy in the treatment of urogenital malignancies.

show abstract

Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept

Cited by 28 publications

References 23 publications

Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer

Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer

Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies

Immunotherapy for genitourinary cancer

Contact Info

Product

Resources

About